

Hans Gelderblom

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2045892/hans-gelderblom-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

552
papers

23,324
citations

76
h-index

136
g-index

612
ext. papers

28,340
ext. citations

5
avg, IF

6.66
L-index

#	Paper	IF	Citations
552	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 379, 1879-86	4.0	1395
551	Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. <i>European Journal of Cancer</i> , 2001 , 37, 1590-8	7.5	1291
550	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 295-302	4.0	908
549	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 415-23	21.7	629
548	Combination chemotherapy in advanced adrenocortical carcinoma. <i>New England Journal of Medicine</i> , 2012 , 366, 2189-97	59.2	510
547	The clinical approach towards chondrosarcoma. <i>Oncologist</i> , 2008 , 13, 320-9	5.7	488
546	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1629-37	4.0	445
545	Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?. <i>European Journal of Cancer</i> , 2011 , 47, 2431-45	7.5	324
544	Clinical pharmacokinetics of tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2009 , 35, 692-706	14.4	316
543	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv51-iv67	10.3	316
542	Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1772-9	2.2	297
541	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2279-87	2.2	260
540	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1396-1408	21.7	253
539	Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. <i>Cancer Research</i> , 1999 , 59, 1454-7	10.1	235
538	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv79-iv95	10.3	223
537	Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii131-8	10.3	222
536	Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. <i>Annals of Oncology</i> , 2015 , 26, 696-701	10.3	218

535	Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv68-iv78	10.3	207
534	Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 38-44	6.1	198
533	Liposomal drug formulations in cancer therapy: 15 years along the road. <i>Drug Discovery Today</i> , 2012 , 17, 160-6	8.8	196
532	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2009 , 161, 923-31	6.5	187
531	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. <i>European Journal of Cancer</i> , 2019 , 109, 36-50	7.5	180
530	EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. <i>Annals of Oncology</i> , 2015 , 26, 407-14	10.3	178
529	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012 , 118, 1649-55	6.4	171
528	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4406-12	2.2	161
527	Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. <i>Clinical Cancer Research</i> , 2008 , 14, 3470-6	12.9	161
526	The clinical approach toward giant cell tumor of bone. <i>Oncologist</i> , 2014 , 19, 550-61	5.7	151
525	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v204-13	10.3	149
524	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 478-487	40	148
523	Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. <i>Cancer Treatment Reviews</i> , 2005 , 31, 90-105	14.4	146
522	Effect of ABCG2 genotype on the oral bioavailability of topotecan. <i>Cancer Biology and Therapy</i> , 2005 , 4, 650-8	4.6	144
521	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology, The</i> , 2018 , 19, 1459-1467	21.7	139
520	Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. <i>Annals of Oncology</i> , 2012 , 23, 1607-16	10.3	138
519	Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. <i>Clinical Cancer Research</i> , 2011 , 17, 620-9	12.9	130
518	Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2423-9	2.2	126

517	First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. <i>Annals of Oncology</i> , 2011 , 22, 207-214	10.3	125
516	RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. <i>European Radiology</i> , 2010 , 20, 1456-67	8	124
515	Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. <i>European Journal of Cancer</i> , 2009 , 45, 2293-7	7.5	123
514	Translating pharmacogenomics: challenges on the road to the clinic. <i>PLoS Medicine</i> , 2007 , 4, e209	11.6	120
513	Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2303-12	2.2	119
512	Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. <i>Annals of Surgical Oncology</i> , 2007 , 14, 942-53	3.1	112
511	Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. <i>European Journal of Cancer</i> , 2007 , 43, 845-51	7.5	111
510	Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. <i>Investigational New Drugs</i> , 2013 , 31, 1087-94	4.3	110
509	Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. <i>Anti-Cancer Drugs</i> , 2014 , 25, 140-9	2.4	109
508	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017 , 28, 1230-1242	10.3	108
507	Factors affecting cytochrome P-450 3A activity in cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 8341-50	12.9	107
506	Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. <i>Annals of Oncology</i> , 2012 , 23, 1680-7	10.3	105
505	Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 4843-50	12.9	105
504	Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. <i>British Journal of Cancer</i> , 2004 , 90, 304-5	8.7	104
503	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 923-934	21.7	102
502	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma	2.2	102
501	Effect of milk thistle (<i>Silybum marianum</i>) on the pharmacokinetics of irinotecan. <i>Clinical Cancer Research</i> , 2005 , 11, 7800-6	12.9	102
500	Inpatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2861-8	2.2	99

499	NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. <i>Molecular Immunology</i> , 2008 , 45, 3917-25	4.3	99
498	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncologica</i> , 2017 , 56, 88-92	3.2	95
497	Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. <i>Annals of Oncology</i> , 2007 , 18, 1745-7	10.3	95
496	Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. <i>International Journal of Cancer</i> , 2004 , 109, 468-71	7.5	94
495	Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. <i>European Journal of Cancer</i> , 2011 , 47, 895-902	7.5	93
494	Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. <i>European Journal of Cancer</i> , 2016 , 58, 62-72	7.5	90
493	Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5094-101	2.2	89
492	Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. <i>Clinical Cancer Research</i> , 2007 , 13, 7394-400	12.9	88
491	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 431-441	35.1	87
490	Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. <i>European Urology</i> , 2014 , 65, 832-8	10.2	87
489	Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. <i>Annals of Oncology</i> , 2012 , 23, 1617-26	10.3	86
488	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1366-1377	21.7	84
487	Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 3758-62	5.6	83
486	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2016 , 54, 40-48	7.5	82
485	Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. <i>Clinical Cancer Research</i> , 2012 , 18, 432-41	12.9	80
484	The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. <i>Nature</i> , 2019 , 574, 127-131	50.4	79
483	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. <i>European Journal of Cancer</i> , 2019 , 109, 51-60	7.5	78
482	Giant cell tumour of bone in the denosumab era. <i>European Journal of Cancer</i> , 2017 , 77, 75-83	7.5	77

481	Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. <i>Clinical Cancer Research</i> , 2011 , 17, 5668-73	12.9	77
480	PD-1 Blockade in Anaplastic Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2620-2627	2.2	76
479	Mitotane has a strong and a durable inducing effect on CYP3A4 activity. <i>European Journal of Endocrinology</i> , 2011 , 164, 621-6	6.5	76
478	Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. <i>Oncologist</i> , 2011 , 16, 1239-49	5.7	75
477	Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1719-1729	21.7	74
476	Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. <i>Oncologist</i> , 2012 , 17, 135-44	5.7	74
475	Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. <i>International Journal of Cancer</i> , 2012 , 131, E74-85	7.5	73
474	Outcome of advanced, unresectable conventional central chondrosarcoma. <i>Cancer</i> , 2014 , 120, 3159-64	6.4	70
473	Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. <i>International Journal of Cancer</i> , 2010 , 127, 899-909	7.5	70
472	Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 503-10	6.1	69
471	Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. <i>Journal of Clinical Oncology</i> , 2002 , 20, 574-81	2.2	69
470	Clinical and pharmacogenetic factors associated with irinotecan toxicity. <i>Cancer Treatment Reviews</i> , 2008 , 34, 656-69	14.4	68
469	Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. <i>Cancer</i> , 2015 , 121, 1405-13	6.4	67
468	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2010 , 46, 1829-34	7.5	67
467	Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 15-21	12.9	67
466	An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. <i>European Journal of Cancer</i> , 2013 , 49, 3219-28	7.5	66
465	Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. <i>Pharmacogenomics Journal</i> , 2013 , 13, 389-95	3.5	65
464	Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 575-86	7.4	64

463	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016 , 6, 15	2.5	64
462	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018782516	2.2	64
461	Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. <i>Clinical Therapeutics</i> , 2013 , 35, 1946-54	3.5	63
460	Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival. <i>European Spine Journal</i> , 2018 , 27, 3043-3058	2.7	62
459	Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. <i>Clinical Cancer Research</i> , 2002 , 8, 1237-41	12.9	62
458	Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. <i>European Journal of Cancer</i> , 2013 , 49, 1027-31	7.5	61
457	Osteosarcoma: evolution of treatment paradigms. <i>Sarcoma</i> , 2013 , 2013, 203531	3.1	61
456	Mammalian target of rapamycin inhibitor-associated stomatitis. <i>Future Oncology</i> , 2013 , 9, 1883-92	3.6	61
455	UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. <i>British Journal of Cancer</i> , 2008 , 99, 275-82	8.7	61
454	Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. <i>European Journal of Cancer</i> , 2010 , 46, 3016-21	7.5	60
453	Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2104-15	2.2	60
452	Individualized dosing of tyrosine kinase inhibitors: are we there yet?. <i>Drug Discovery Today</i> , 2015 , 20, 18-36	8.8	59
451	A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 937, 33-43	3.2	59
450	Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. <i>British Journal of Cancer</i> , 2011 , 104, 37-42	8.7	59
449	Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. <i>British Journal of Cancer</i> , 2009 , 101, 1909-18	8.7	58
448	Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. <i>British Journal of Cancer</i> , 2013 , 109, 1214-22	8.7	57
447	Survival of patients with ovarian cancer due to a mismatch repair defect. <i>Familial Cancer</i> , 2005 , 4, 301-5	3	57
446	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with -mutated or -mutated solid tumours. <i>BMJ Open</i> , 2017 , 7, e014961	3	55

445	CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. <i>European Urology</i> , 2015 , 68, 621-9	10.2	55
444	Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 81-9	6.1	54
443	New treatment modalities in advanced thyroid cancer. <i>Annals of Oncology</i> , 2012 , 23, 10-18	10.3	54
442	Adjuvant therapy in primary GIST: state-of-the-art. <i>Annals of Oncology</i> , 2012 , 23, 2776-2781	10.3	54
441	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017 , 72, 156-165	7.5	53
440	Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. <i>Pharmacogenomics</i> , 2015 , 16, 1277-86	2.6	53
439	Prognostic factors in pulmonary metastasized high-grade osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2010 , 54, 216-21	3	53
438	Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 636-646	2.2	52
437	The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact. <i>Histopathology</i> , 2018 , 73, 197-206	7.3	52
436	Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. <i>European Journal of Surgical Oncology</i> , 2013 , 39, 150-5	3.6	52
435	Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 874, 84-8	3.2	52
434	Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 1021-48	3.1	51
433	Higher incidence rates than previously known in tenosynovial giant cell tumors. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2017 , 88, 688-694	4.3	50
432	A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. <i>Acta Oncologica</i> , 2015 , 54, 1195-201	3.2	49
431	Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2009 , 45, 572-8	7.5	48
430	Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 1348-1365	10.3	48
429	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1384-1390	3.6	47
428	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 639-648	21.7	47

427	Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. <i>Cancer Treatment Reviews</i> , 2012 , 38, 505-14	14.4	47
426	Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. <i>Sarcoma</i> , 2012 , 2012, 740279	3.1	47
425	CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 583-90	4.4	46
424	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , 2018 , 4, e180219	13.4	46
423	STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11001-11001	2.2	46
422	High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3192-3202	2.2	45
421	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'. <i>Annals of Oncology</i> , 2018 , 29, 758-765	10.3	44
420	Addition of interferon- β to the p53-SLP β vaccine results in increased production of interferon- β in vaccinated colorectal cancer patients: a phase I/II clinical trial. <i>International Journal of Cancer</i> , 2013 , 132, 1581-91	7.5	44
419	Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 698-707	5.6	43
418	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016 , 16, 22	4.8	43
417	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018 , 23, 62-70	5.7	42
416	Prognostic factors for survival in Ewing sarcoma: A systematic review. <i>Surgical Oncology</i> , 2018 , 27, 603-610	6.0	41
415	Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 331-8	3.2	41
414	Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1543-7	6.7	41
413	Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 1049-63	3.5	40
412	Pharmacogenetics of EGFR and VEGF inhibition. <i>Drug Discovery Today</i> , 2007 , 12, 1054-60	8.8	40
411	Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. <i>PLoS ONE</i> , 2014 , 9, e115869	3.7	40
410	CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 363-73	4.4	39

409	Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. <i>European Journal of Cancer</i> , 2012 , 48, 703-12	7.5	39
408	Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4169-76	2.2	39
407	Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 111-8	6.1	39
406	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020 , 31, 1506-1517	10.3	39
405	A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal. <i>Journal of Surgical Oncology</i> , 2013 , 107, 433-45	2.8	38
404	Reversibility of capillary density after discontinuation of bevacizumab treatment. <i>Annals of Oncology</i> , 2010 , 21, 1100-5	10.3	38
403	Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. <i>Annals of Surgical Oncology</i> , 2008 , 15, 1891-8	3.1	38
402	Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions. <i>Journal of Clinical Oncology</i> , 2002 , 20, 574-581	2.2	38
401	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 87-95	3.5	37
400	Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. <i>Annals of Oncology</i> , 2008 , 19, 1127-34	10.3	37
399	Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 523-536	3.8	36
398	Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1479-1485	12.9	36
397	Marginal increase of sunitinib exposure by grapefruit juice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 695-703	3.5	36
396	A phase II study of a human anti-PDGFR β monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. <i>Annals of Oncology</i> , 2017 , 28, 541-546	10.3	35
395	Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. <i>European Journal of Cancer</i> , 2016 , 53, 171-80	7.5	35
394	Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. <i>Clinical Sarcoma Research</i> , 2014 , 4, 14	2.5	35
393	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. <i>Lancet Oncology</i> , 2019 , 20, 877-886	21.7	34
392	Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). <i>Annals of Oncology</i> , 2015 , 26, 865-872	10.3	34

391	Achievements in colorectal cancer care during 8 years of auditing in The Netherlands. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1361-1370	3.6	34
390	Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. <i>Clinical Cancer Research</i> , 2003 , 9, 4101-7	12.9	34
389	Xerosis and pruritus as major EGFR-associated adverse events. <i>Supportive Care in Cancer</i> , 2016 , 24, 513-521	5.2	33
388	CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. <i>International Journal of Cancer</i> , 2015 , 136, E760-72	7.5	33
387	Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 519-29	2.8	33
386	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors 2020 , 8,		32
385	Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 243-7	1.9	32
384	Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. <i>International Journal of Endocrinology</i> , 2015 , 2015, 348127	2.7	32
383	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020 , 126, 2637-2647	6.4	31
382	Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases. <i>Clinical Cancer Research</i> , 2013 , 19, 5822-7	12.9	31
381	Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. <i>European Journal of Endocrinology</i> , 2008 , 158, 911-9	6.5	31
380	Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6024-6024	2.2	31
379	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3294-3303	2.2	31
378	Inter- and inpatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. <i>Clinical Cancer Research</i> , 2000 , 6, 2685-9	12.9	31
377	Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2632-2638	3.1	30
376	Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. <i>Clinical Sarcoma Research</i> , 2014 , 4, 11	2.5	30
375	Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. <i>Head and Neck</i> , 2017 , 39, 140-146	4.2	30
374	Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. <i>British Journal of Cancer</i> , 2009 , 101, 357-62	8.7	30

373	Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2011 , 22, 1147-1153	10.3	30
372	Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. <i>Current Opinion in Oncology</i> , 2019 , 31, 329-335	4.2	30
371	A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019 , 107, 60-67	7.5	30
370	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. <i>Clinical Cancer Research</i> , 2015 , 21, 3436-41	12.9	29
369	HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases. <i>Human Immunology</i> , 2016 , 77, 773-9	2.3	28
368	Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 1589-1598	2.8	28
367	Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. <i>European Journal of Cancer</i> , 2014 , 50, 388-96	7.5	28
366	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. <i>Future Oncology</i> , 2020 , 16, 4251-4264	3.6	28
365	Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. <i>Current Opinion in Oncology</i> , 2016 , 28, 314-22	4.2	28
364	Perioperative Management of Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2018 , 36, 118-124	2.2	28
363	Influenza vaccination in adult patients with solid tumours treated with chemotherapy. <i>European Journal of Cancer</i> , 2017 , 76, 134-143	7.5	27
362	Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 599-606	4.4	27
361	Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. <i>Clinical Sarcoma Research</i> , 2011 , 1, 5	2.5	27
360	Therapeutic modulation of k-ras signaling in colorectal cancer. <i>Drug Discovery Today</i> , 2010 , 15, 502-16	8.8	27
359	Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. <i>European Journal of Cancer</i> , 2016 , 52, 77-84	7.5	25
358	Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 1035-48	3.5	25
357	Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial. <i>Clinical Orthopaedics and Related Research</i> , 2020 , 478, 290-302	2.2	25
356	Tumor LINE-1 Methylation Level in Association with Survival of Patients with Stage II Colon Cancer. <i>International Journal of Molecular Sciences</i> , 2016 , 18,	6.3	24

355	Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1547-53	8.9	24
354	GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. <i>British Journal of Cancer</i> , 2008 , 99, 1316-21	8.7	24
353	Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. <i>European Journal of Surgical Oncology</i> , 2007 , 33, 874-81	3.6	24
352	Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. <i>PLoS ONE</i> , 2014 , 9, e112201	3.7	24
351	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. <i>Oncologist</i> , 2019 , 24, 110-116	5.7	23
350	Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. <i>Pharmacogenomics</i> , 2013 , 14, 2005-12	2.6	23
349	A single digital droplet PCR assay to detect multiple exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. <i>Oncotarget</i> , 2018 , 9, 13870-13883	3.3	23
348	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). <i>International Journal of Cancer</i> , 2018 , 142, 2610-2620	7.5	22
347	Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 63-71	3.5	22
346	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 1344-50	2.9	22
345	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 1089-98	3.5	22
344	Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2015 , 33, 1242-7	4.3	21
343	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. <i>European Journal of Cancer</i> , 2020 , 134, 62-74	7.5	21
342	Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. <i>Laboratory Investigation</i> , 2016 , 96, 1128-37	5.9	21
341	Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2016 , 18, 3	8.3	21
340	Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 238-250.e1	3.3	21
339	Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. <i>Acta Oncologica</i> , 2017 , 56, 1769-1775	3.2	21
338	Diflomotecan, a promising homocamptothecin for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 69-75	5.9	21

337	Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 1168-76	2.8	21
336	False-positive serum human chorionic gonadotropin (HCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literature. <i>Oncologist</i> , 2008 , 13, 1149-54	5.7	21
335	Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. <i>World Journal of Surgical Oncology</i> , 2018 , 16, 191	3.4	21
334	Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. <i>European Journal of Cancer</i> , 2017 , 76, 76-83	7.5	20
333	HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and western blot analysis: Its expression characteristics remain enigmatic. <i>Clinical Immunology</i> , 2018 , 194, 80-86	9	20
332	The use of the ¹³ C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 593-601	3.5	20
331	In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines. <i>Journal of Surgical Research</i> , 2011 , 167, 273-8	2.5	20
330	Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. <i>Annals of Oncology</i> , 2010 , 21, 1662-1667	10.3	20
329	Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity. <i>Current Cancer Drug Targets</i> , 2007 , 7, 504-9	2.8	20
328	Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 766, 99-105	3.2	20
327	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10503-10503	2.2	20
326	Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11500-11500	2.2	20
325	Early Evaluation of Response Using F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 194-196	8.9	19
324	Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series. <i>Clinical Sarcoma Research</i> , 2016 , 6, 19	2.5	19
323	Myelosuppression by sunitinib is flt-3 genotype dependent. <i>British Journal of Cancer</i> , 2010 , 103, 757-8	8.7	19
322	Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. <i>Clinical Cancer Research</i> , 2008 , 14, 8308-13	12.9	19
321	Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 1520-1536	10.3	19
320	Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 58-65	3.2	18

319	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1477-84	2.8	18
318	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , 2018 , 23, 1250-1259	5.7	18
317	The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 472, 221-229	5.1	18
316	Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. <i>Clinical Cancer Research</i> , 2018 , 24, 2678-2687	12.9	18
315	Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2018 , 89, 570-574	4.3	18
314	Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 462, 109-20	5.1	18
313	Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 87-96	3.5	18
312	Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. <i>Journal of Cutaneous Pathology</i> , 2009 , 36, 565-9	1.7	18
311	Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 3620-3629	12.9	18
310	Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 553-61	3.8	18
309	New systemic therapy options for advanced sarcomas. <i>Current Treatment Options in Oncology</i> , 2012 , 13, 306-17	5.4	17
308	A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11078-11078	2.2	17
307	Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. <i>Oncotarget</i> , 2014 , 5, 7357-67	3.3	17
306	Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2020 , 141, 9-20	7.5	17
305	Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. <i>Pharmacogenomics</i> , 2016 , 17, 721-9	2.6	17
304	Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma. <i>Sarcoma</i> , 2017 , 2017, 2372135	3.1	16
303	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019 , 9, 14551	4.9	16
302	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA10502-LBA10502	2.2	16

301	Tissue factor associates with survival and regulates tumour progression in osteosarcoma. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 1025-33	7	16
300	Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 ,	10.3	16
299	Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1124-1130	3.6	15
298	Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model: A multistate model for Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27943	3	15
297	Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. <i>Supportive Care in Cancer</i> , 2013 , 21, 1919-26	3.9	15
296	Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 941-7	7.4	15
295	Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. <i>Drug Metabolism and Disposition</i> , 1999 , 27, 1300-5	4	15
294	Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. <i>Pharmacogenomics Journal</i> , 2017 , 17, 42-46	3.5	14
293	Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 40-4	3	14
292	Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27011	3	14
291	Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. <i>Investigational New Drugs</i> , 2011 , 29, 137-43	4.3	14
290	Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. <i>Investigational New Drugs</i> , 2011 , 29, 953-62	4.3	14
289	Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. <i>British Journal of Cancer</i> , 2010 , 102, 1699-706	8.7	14
288	Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1197-210	4	14
287	MAP plus maintenance pegylated interferon β (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA10504-LBA10504	2.2	14
286	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11502-11502	2.2	14
285	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104	6.4	14
284	Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2015 , 86, 393-5	4.3	13

283	Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. <i>Oncologist</i> , 2021 , 26, e1347-e1358	5.7	13
282	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. <i>BMC Cancer</i> , 2019 , 19, 794	4.8	13
281	Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 1557-63	3.6	13
280	The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. <i>Pharmacogenomics</i> , 2017 , 18, 1125-1132	2.6	13
279	Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. <i>Journal of Medical Economics</i> , 2013 , 16, 1106-19	2.4	13
278	MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 208-18	1.9	13
277	Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies. <i>European Journal of Cancer</i> , 2002 , 38, 205-13	7.5	13
276	Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. <i>Gynecologic Oncology</i> , 2016 , 142, 95-101	4.9	13
275	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study). <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 1076-1082	6.1	12
274	Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 307-15	3.6	12
273	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 605-18	3.8	12
272	A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. <i>BMC Cancer</i> , 2018 , 18, 92	4.8	12
271	Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 401-411	4.4	12
270	Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Anti-Cancer Drugs</i> , 2015 , 26, 872-7	2.4	12
269	Gastrointestinal stromal tumor in pregnancy: a case report. <i>Case Reports in Medicine</i> , 2009 , 2009, 456402	2.7	12
268	Pharmacogenetics in oncology: a promising field. <i>Current Pharmaceutical Design</i> , 2010 , 16, 155-63	3.3	12
267	Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis. <i>Anti-Cancer Drugs</i> , 2003 , 14, 227-32	2.4	12
266	Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2001 , 85, 1124-9	8.7	12

265	Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?. <i>European Journal of Cancer</i> , 2018 , 89, 1-8	7.5	12
264	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. <i>European Journal of Cancer</i> , 2017 , 86, 226-232	7.5	11
263	The significance of stromal collagen organization in cancer tissue: An in-depth discussion of literature. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102907	7	11
262	Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 383-5	6.1	11
261	Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. <i>BMC Cancer</i> , 2014 , 14, 575	4.8	11
260	Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 1303-6	3.5	11
259	Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. <i>European Journal of Cancer</i> , 2015 , 51, 2453-64	7.5	11
258	Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle. <i>Pharmacogenomics</i> , 2010 , 11, 1011-7	2.6	11
257	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021 , 127, 2934-2942	6.4	11
256	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021 , 6, 100170	6	11
255	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. <i>Prostate</i> , 2016 , 76, 32-40	4.2	11
254	Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. <i>Nature Medicine</i> , 2021 , 27, 1553-1563	50.5	11
253	Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial. <i>Oncologist</i> , 2019 , 24, 889-e421	5.7	10
252	Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. <i>Acta Oncologica</i> , 2019 , 58, 872-879	3.2	10
251	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , 2020 , 122, 1158-1165	8.7	10
250	Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies. <i>Clinical Cancer Research</i> , 2018 , 24, 3465-3474	12.9	10
249	Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2013 , 169, 51-8	6.5	10
248	Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring. <i>European Journal of Endocrinology</i> , 2014 , 171, 677-83	6.5	10

247	Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2014 , 759, 37-44	3.3	10
246	Pharmacogenetics in chemotherapy of colorectal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2009 , 23, 257-73	2.5	10
245	Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2015-2015	2.2	10
244	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 651-658	6.2	10
243	Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 741-758	4.4	10
242	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. <i>Cancer</i> , 2019 , 125, 2445-2454	6.4	9
241	A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 951-962	3.5	9
240	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. <i>Acta Oncologica</i> , 2018 , 57, 1117-1126	3.2	9
239	Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. <i>Scientific Reports</i> , 2019 , 9, 11000	4.9	9
238	Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 429-33	3.5	9
237	CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study. <i>Drugs and Aging</i> , 2015 , 32, 1019-27	4.7	9
236	CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 171-9	4.4	9
235	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA10008-LBA10008	2.2	9
234	A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3060-3060	2.2	9
233	Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11006-11006 ⁹	2.2	9
232	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. <i>Oncology</i> , 2016 , 91, 267-273	3.6	9
231	Phase 1/2A Study of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (Bm) from Solid Tumors or Recurrent High Grade Gliomas (Hgg). <i>Annals of Oncology</i> , 2014 , 25, iv157	10.3	8
230	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. <i>Translational Oncology</i> , 2017 , 10, 546-554	4.9	8

229	Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015 , 10, e0131091	3.7	8
228	Phenotyping drug disposition in oncology. <i>Cancer Treatment Reviews</i> , 2012 , 38, 715-25	14.4	8
227	Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 635-61	5.9	8
226	Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 3091-3097	10.3	8
225	Distribution of paclitaxel in plasma and cerebrospinal fluid. <i>Anti-Cancer Drugs</i> , 2003 , 14, 365-8	2.4	8
224	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020 , 5,	6	8
223	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021 , 10, 2645-2659	4.8	8
222	Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy. <i>British Journal of Cancer</i> , 2016 , 114, 1219-26	8.7	8
221	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021 , 26, e863-e873	5.7	8
220	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , 2021 , 127, 884-893	6.4	8
219	DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A. <i>Annals of Oncology</i> , 2018 , 29, viii150	10.3	8
218	Exposure-response analysis of endoxifen serum concentrations in early-breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 1141-1152	3.5	7
217	Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases. <i>Case Reports in Orthopedics</i> , 2017 , 2017, 7402570	0.4	7
216	Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy. <i>OncoTargets and Therapy</i> , 2017 , 10, 2963-2970	4.4	7
215	A Genetic Polymorphism in Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 2350-2356	12.9	7
214	Promoter methylation and mRNA expression of HLA-G in relation to HLA-G protein expression in colorectal cancer. <i>Human Immunology</i> , 2016 , 77, 764-72	2.3	7
213	Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 179-182	3.5	7
212	INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753). <i>Annals of Oncology</i> , 2019 , 30, v825-v826	10.3	7

211	Further characterization of a ^{14}C -dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy. <i>Journal of Breath Research</i> , 2015 , 9, 026003	3.1	7
210	Results of a Randomised Phase III Trial (EORTC 62012) of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide as First Line Chemotherapy for Patients with Advanced or Metastatic Soft Tissue Sarcoma: A Survival Study by the Eortc Soft Tissue and Bone Sarcoma Group. <i>Annals of Oncology</i> , 2012 , 23, ix228	10.3	7
209	International evaluation of circumferential resection margins after rectal cancer resection: insights from the Swedish and Dutch audits. <i>Colorectal Disease</i> , 2020 , 22, 416-429	2.1	7
208	Panobinostat-A Potential Treatment for Metastasized Ewing Sarcoma? A Case Report. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1840-3	3	7
207	Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 591-604	6.1	7
206	Topotecan lacks third space sequestration. <i>Clinical Cancer Research</i> , 2000 , 6, 1288-92	12.9	7
205	F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma. <i>Skeletal Radiology</i> , 2019 , 48, 1735-1746	2.7	6
204	Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib. <i>Pharmacogenomics Journal</i> , 2018 , 18, 49-55	3.5	6
203	Tales of how great drugs were brought down by a flawed rationale--letter. <i>Clinical Cancer Research</i> , 2013 , 19, 1303	12.9	6
202	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10516-10516	2.2	6
201	A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3113-TPS3113	2.2	6
200	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11574-11574	2.2	6
199	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11023-11023	2.2	6
198	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 69-76.e4	3.3	6
197	Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma. <i>Cancers</i> , 2020 , 12,	6.6	6
196	Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. <i>Future Oncology</i> , 2020 , 16, 2345-2356	3.6	6
195	Home treatment of patients with cancer-associated venous thromboembolism - An evaluation of daily practice. <i>Thrombosis Research</i> , 2019 , 184, 122-128	8.2	6
194	Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 410-415	3.6	6

193	Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 143-152	5.9	6
192	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. <i>Sarcoma</i> , 2018 , 2018, 5982575	7.1	6
191	Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet. <i>Current Opinion in Molecular Therapeutics</i> , 2010 , 12, 654-61		6
190	Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study. <i>Clinical Sarcoma Research</i> , 2017 , 7, 2	2.5	5
189	Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 47-52	3.5	5
188	Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database. <i>European Journal of Cancer Care</i> , 2015 , 24, 232-41	2.4	5
187	Current concepts in the treatment of giant cell tumour of bone. <i>Current Opinion in Oncology</i> , 2020 , 32, 332-338	4.2	5
186	Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. <i>European Journal of Cancer</i> , 2018 , 94, 187-198	7.5	5
185	Current clinical trials for advanced osteosarcoma and soft tissue sarcoma. <i>Current Opinion in Oncology</i> , 2014 , 26, 434-9	4.2	5
184	Is rectal administration an alternative route for imatinib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 60, 623-4	3.5	5
183	VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3037-3037	2.2	5
182	Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 562-562	2.2	5
181	Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017 , 8, 1204-1212	3.3	5
180	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , 2018 , 9, 34617-34627	3.3	5
179	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants</i> . <i>Genes</i> , 2018 , 9,	10.3	5
178	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018 , 104, 210-218	4.2	5
177	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018 , 104, 210-218	7.5	5
176	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA". <i>European Journal of Cancer</i> , 2021 , 158, 26-40	7.5	5

175	Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26457	3	4
174	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 227-231	1.9	4
173	Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia. <i>Pharmacogenomics</i> , 2015 , 16, 1267-76	2.6	4
172	Treatment strategies and overall survival for incurable metastatic colorectal cancer - A EURECCA international comparison including 21,196 patients from the Netherlands and Norway. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1167-1173	3.6	4
171	Breath tests to phenotype drug disposition in oncology. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 919-26	6.2	4
170	Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2312-2314	3.8	4
169	The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. <i>Investigational New Drugs</i> , 2012 , 30, 1208-10	4.3	4
168	Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. <i>European Journal of Oncology Nursing</i> , 2013 , 17, 802-7	2.8	4
167	Osteosarcoma: lessons learned and future avenues. <i>Sarcoma</i> , 2013 , 2013, 641687	3.1	4
166	SNPs and haplotypes in DPYD and outcome of capecitabine--Letter. <i>Clinical Cancer Research</i> , 2011 , 17, 5833-4; author reply 5835-6	12.9	4
165	VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. <i>Vascular Pharmacology</i> , 2006 , 45, e42-e43	5.9	4
164	Prognostic stratification using the nomogram sarculator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11518-11518	2.2	4
163	Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11042-11042	2.2	4
162	Quality of life (QoL) and self-reported function with ripretinib in 4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11535-11535	2.2	4
161	Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients. <i>European Journal of Cancer</i> , 2020 , 141, 128-136	7.5	4
160	Selection of Effective Therapies Using Three-Dimensional Modeling of Chondrosarcoma. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 566291	5.6	4
159	Gastrointestinal Stromal Tumours (GIST) in Young Adult (18-40 Years) Patients: A Report from the Dutch GIST Registry. <i>Cancers</i> , 2020 , 12,	6.6	4
158	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021 , 27, 6333-6342	12.9	4

157	Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study. <i>Annals of Oncology</i> , 2019 , 30, v161	10.3	3
156	Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. <i>Cellular Oncology (Dordrecht)</i> , 2019 , 42, 717-725	7.2	3
155	1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study. <i>Annals of Oncology</i> , 2020 , 31, S974-S975	10.3	3
154	Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study. <i>Annals of Oncology</i> , 2017 , 28, v645-v646	10.3	3
153	The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2399-2404	3.8	3
152	Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs). <i>Annals of Oncology</i> , 2019 , 30, v695-v696	10.3	3
151	Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 1701-7	6.7	3
150	Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. <i>Clinical Investigation</i> , 2011 , 1, 241-253		3
149	Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians. <i>International Journal of Biological Markers</i> , 2012 , 27, 34-8	2.8	3
148	72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. <i>European Journal of Cancer, Supplement</i> , 2006 , 4, 26	1.6	3
147	Pharmacokinetics (PK) of free and total paclitaxel after equal doses of paclitaxel injectable emulsion and paclitaxel injection. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2045-2045	2.2	3
146	Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study. <i>Journal of Clinical Oncology</i> , 2009 , 27, CRA509-CRA509	2.2	3
145	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10006-10006	2.2	3
144	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA10502-LBA10502	2.2	3
143	Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: Report from the International Ewing 2008R3 trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11501-11501	2.2	3
142	Efficacy of maintenance therapy with zoledronic acid in patients with localized Ewing sarcoma: Report from the international Ewing 2008 trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11523-11523	2.2	3
141	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in Fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11539-11539	2.2	3
140	Outcome of Surgical Treatment for Patients with Diffuse-Type Tenosynovial Giant Cell Tumours. <i>SSRN Electronic Journal</i> ,	1	3

139	Therapy-Related Imaging Findings in Patients with Sarcoma. <i>Seminars in Musculoskeletal Radiology</i> , 2020 , 24, 676-691	1.8	3
138	Nationwide analysis of hospital variation in preoperative radiotherapy use for rectal cancer following guideline revision. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 486-494	3.6	3
137	Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma. <i>Oncologist</i> , 2020 , 25, e716-e721	5.7	3
136	Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study. <i>Clinical Sarcoma Research</i> , 2020 , 10, 18	2.5	3
135	Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. <i>European Journal of Radiology</i> , 2020 , 133, 109345	4.7	3
134	Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in and and Methotrexate Levels and Toxicities. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1241	5.6	3
133	The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 191	4.2	3
132	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3574-3574	2.2	3
131	Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma. <i>BMJ Open</i> , 2019 , 9, e022980	3	3
130	Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1925-1931	3.6	3
129	Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center. <i>Cancers</i> , 2021 , 13,	6.6	3
128	Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. <i>PLoS ONE</i> , 2018 , 13, e0208080	3.7	3
127	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. <i>Oncologist</i> , 2021 , 26, e2053-e2060	5.7	3
126	Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. <i>Scientific Reports</i> , 2021 , 11, 415	4.9	3
125	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. <i>Pharmacogenomics Journal</i> , 2019 , 19, 473-479	3.5	2
124	Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1984-1985		2
123	Using a quality of life (QoL)-monitor: preliminary results of a randomized trial in Dutch patients with early breast cancer. <i>Quality of Life Research</i> , 2020 , 29, 2961-2975	3.7	2
122	Primary Ewing sarcoma of the iris. <i>Lancet, The</i> , 2014 , 383, 256	4.0	2

121	Pharmacogenetics of Chemotherapy Response in Osteosarcoma: A Genetic Variant in SLC7A8 is Associated with Progressive Disease. <i>Clinical Therapeutics</i> , 2017 , 39, e10	3.5	2
120	Should rectal cancer located 10-15 cm from the anal verge be defined as colon cancer. <i>Annals of Oncology</i> , 2017 , 28, 664-665	10.3	2
119	Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 920-5	2.9	2
118	Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. <i>Annals of Oncology</i> , 2012 , 23, ix478-ix479	10.3	2
117	Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.. <i>Lancet Oncology, The</i> , 2022 , 23, 198-201	21.7	2
116	Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses.. <i>Breast Cancer Research and Treatment</i> , 2022 , 192, 603	4.4	2
115	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10009-10009	2.2	2
114	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10081-10081	2.2	2
113	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10512-10512	2.2	2
112	Food intervention to make therapy with pazopanib more patient-friendly and affordable.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11040-11040	2.2	2
111	Neoadjuvant denosumab treatment of locally advanced giant cell tumor of bone (GCTB).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11026-11026	2.2	2
110	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11065-11065	2.2	2
109	First prospective observational study in diffuse-type tenosynovial giant cell tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11560-11560	2.2	2
108	A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 523-523	2.2	2
107	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4564-4564	2.2	2
106	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.. <i>European Journal of Cancer</i> , 2022 , 162, 148-157	7.5	2
105	Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer. <i>Cells</i> , 2021 , 10,	7.9	2
104	MAP plus maintenance pegylated interferon β b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA10504-LBA10504	2.2	2

103	594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients. <i>Annals of Oncology</i> , 2020 , 31, S498	10.3	2
102	Personalising sarcoma care using quantitative multimodality imaging for response assessment. <i>Clinical Radiology</i> , 2021 , 76, 313.e1-313.e13	2.9	2
101	Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice. <i>Gastric Cancer</i> , 2021 , 24, 990-1002	7.6	2
100	Management of tenosynovial giant cell tumour of the foot and ankle. <i>Bone and Joint Journal</i> , 2021 , 103-B, 788-794	5.6	2
99	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 89-102	6.2	2
98	Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2018 , 26, 1233-1242	3.9	2
97	Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy. <i>Head and Neck</i> , 2019 , 41, 488-494	4.2	2
96	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021 , 155, 236-244	7.5	2
95	Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study. <i>ESMO Open</i> , 2021 , 6, 100258	6	2
94	The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC.. <i>European Journal of Cancer</i> , 2022 , 165, 71-80	7.5	2
93	Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil. <i>Journal of Gastrointestinal Cancer</i> , 2017 , 48, 117-118	1.6	1
92	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. <i>Sarcoma</i> , 2019 , 2019, 3234205	3.1	1
91	Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 348	18.1	1
90	Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011 , 1, 118-23	2.2	1
89	Influence of the cisplatin hydration schedule on topotecan pharmacokinetics. <i>European Journal of Cancer</i> , 2003 , 39, 1542-6	7.5	1
88	Association of the genetic variants in the nucleotide excision repair genes XPA and XPC with cisplatin-induced hearing loss in patients with osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10077-10077	2.2	1
87	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA10008-LBA10008	2.2	1
86	CYP3A4 phenotyping with midazolam to predict sunitinib exposure.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2592-2592	2.2	1

85	Induction chemotherapy (IC) with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing concomitant chemoradiotherapy (CRT) in fit patients with locally advanced head and neck cancer (LAHNC): The CONDOR study. A study of the Dutch Head and Neck Society.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6057-6057	2.2	1
84	Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e22152-e22152	2.2	1
83	Association of genetic variants involved in drug metabolism and transport with efficacy and toxicity of chemotherapeutic treatment in osteosarcoma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10038-10038	2.2	1
82	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10549-10549	2.2	1
81	Clinical characteristics and treatment outcome in a large multicenter observational cohort of pdgfra exon 18 mutated gastrointestinal stromal tumor (GIST) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11011-11011	2.2	1
80	Prognostic factors for local control in Ewing sarcoma (ES) in the Euro-EWING99 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11026-11026	2.2	1
79	The impact of gastric acid suppressive agents on pazopanib exposure.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16076-e16076	2.2	1
78	Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18236-e18236	2.2	1
77	SELNET clinical practice guidelines for soft tissue sarcoma and GIST. <i>Cancer Treatment Reviews</i> , 2021 , 102, 102312	14.4	1
76	Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. <i>Cancers</i> , 2021 , 13,	6.6	1
75	Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3598-3598	2.2	1
74	A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS10577-TPS10577	2.2	1
73	Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs). <i>Journal of Clinical Oncology</i> , 2009 , 27, e13520-e13520	2.2	1
72	Bevacizumab-related hypertension: Search for underlying mechanisms. <i>Journal of Clinical Oncology</i> , 2009 , 27, e14520-e14520	2.2	1
71	Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10551-10551	2.2	1
70	Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2020 , 11, 577968	5.6	1
69	Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11502-11502	2.2	1
68	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11566-11566	2.2	1

67	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021 , 92, 493-499	4.3	1
66	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 480-492	2.9	1
65	The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. <i>Scientific Reports</i> , 2021 , 11, 3249	4.9	1
64	Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000-2017 Netherlands Cancer Registry Database Analysis. <i>Sarcoma</i> , 2021 , 2021, 9976122	3.1	1
63	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2173-2181	3.6	1
62	Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 1422-1432	4.5	1
61	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2021 , 154, 253-268	7.5	1
60	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021 , 27, 6106-6114	12.9	1
59	A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. <i>Acta Oncologica</i> , 2021 , 60, 1557-1564	3.2	1
58	The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. <i>International Journal of Cancer</i> , 2021 , 148, 2799-2806	7.5	1
57	The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer.. <i>Cancers</i> , 2021 , 14,	6.6	1
56	High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101942	2.2	1
55	A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.. <i>BMC Cancer</i> , 2022 , 22, 511	4.8	1
54	Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent. <i>Nuklearmedizin - NuclearMedicine</i> , 2021 , 60, 411-416	1.8	0
53	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11540-11540	2.2	0
52	Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11564-11564	2.2	0
51	Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2614-2614	2.3	0
50	Prospective practice survey of management of cetuximab-related skin reactions. <i>Supportive Care in Cancer</i> , 2021 , 29, 3497-3506	3.9	0

49	Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	o
48	Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial.. <i>BMJ Open</i> , 2022 , 12, e052941	3	o
47	Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature. <i>Cancer Chemotherapy and Pharmacology</i> ,	3.5	o
46	Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists. <i>Annals of Oncology</i> , 2016 , 27, 752	10.3	
45	In reply. <i>Oncologist</i> , 2014 , 19, 1208	5.7	
44	Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'. <i>British Journal of Cancer</i> , 2010 , 102, 1791-2	8.7	
43	Reply to R. Ferraldeschi et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e586-e586	2.2	
42	Topoisomerase inhibitors 2006 , 83-100		
41	Pharmacological Background 2007 , 19-28		
40	Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5026-5026	2.2	
39	Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3149-TPS3149	2.2	
38	The effect of gastrectomy in regorafenib treated GIST patients on outcome and drug exposure.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e22511-e22511	2.2	
37	Olaparib monotherapy in pretreated patients with BRCA1/2 alterations: Results of a DRUP trial cohort.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3633-3633	2.2	
36	Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11556-11556	2.2	
35	Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e23565-e23565	2.2	
34	Quality of life of patients with locally advanced head and neck cancer (LAHNC) treated with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6053-6053	2.2	
33	Sensitivity and specificity of an oral uracil-loading test dose for screening for DPD deficiency.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11101-11101	2.2	
32	Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11074-11074	2.2	

31	Osteosarcoma of the head and neck (OHN): A multicenter case series of 79 adult patients in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10542-10542	2.2
30	CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4548-4548	2.2
29	Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10561-10561	2.2
28	Pharmacogenetic markers for efficacy and toxicity of chemotherapy in osteosarcoma patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10054-10054	2.2
27	Association of pharmacogenetic variants with progressive disease in osteosarcoma patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10057-10057	2.2
26	Association of hematological toxicity (tox) and outcome to doxorubicin (DOX) in advanced soft tissue sarcoma (STS): A retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10544-10544	2.2
25	Investigating the heterogeneity of alkylating agents efficacy between genders: A meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e21500-e21500	2.2
24	Evaluation of quality of life at progression in patients with soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11015-11015	2.2
23	Causal effects of methotrexate reductions/delays in treatment of high-grade resectable osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e22502-e22502	2.2
22	The Drug Rediscovery Protocol (DRUP).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2547-2547	2.2
21	Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study. <i>Blood</i> , 2011 , 118, 5007-5007	2.2
20	Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10518-10518	2.2
19	Common polymorphisms in the estrogen receptor-1 may determine risk of hot flashes in early breast cancer patients using tamoxifen.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 526-526	2.2
18	Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10067-10067	2.2
17	Health care utilization (HCU) by breast cancer (BC) and non-Hodgkin lymphoma (NHL) patients (pts) with chemotherapy (CT) induced febrile neutropenia (FN) in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e16526-e16526	2.2
16	Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 594-594	2.2
15	Simultaneous assessment of targeted anticancer therapy-associated mucocutaneous adverse events.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20669-e20669	2.2
14	The influence of gastrointestinal resection on sunitinib exposure in GIST patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10547-10547	2.2

13	Safety and efficacy of the addition of simvastatin to panitumumab in KRAS mutant metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14558-e14558	2.2
12	Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 595-595	2.2
11	Phase II multicenter clinical trial of isolated lung perfusion (ILuP) with melphalan (MN) in patients (pts) with resectable lung metastases (LM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7534-7534	2.2
10	CYP2D6 genotype related to tamoxifen efficacy: An analysis with exclusion of potential false CYP2D6 genotype assignment caused by loss of heterozygosity in tumor tissue.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 597-597	2.2
9	Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4580-4580	2.2
8	Safety and efficacy of the addition of simvastatin to cetuximab in KRAS mutant metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14586-e14586	2.2
7	Dynamic prediction of overall survival: a retrospective analysis on 979 patients with Ewing sarcoma from the German registry. <i>BMJ Open</i> , 2020 , 10, e036376	3
6	Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11536-11536	2.2
5	National survey on access to new oncology drugs pending health technology assessment and financial arrangements.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e13599-e13599	2.2
4	COVID-19 and systemic anticancer therapy: exploiting uncertainty. <i>Lancet Oncology</i> , 2021 , 22, 3-5	2.1.7
3	Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial.. <i>BMJ Open</i> , 2022 , 12, e053083	3
2	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database.. <i>Sarcoma</i> , 2022 , 2022, 5815875	3.1
1	Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma.. <i>BMJ Open</i> , 2021 , 11, e053456	3